|
|
Post by hellodolly on May 15, 2018 14:39:40 GMT -5
Once company achieves break even point (within 18 months IMO) there will be interest. After the pediatric approval there will be multiple offers. But... Afrezza is not for sale. Afrezza is not for sale but Mannkind is, and the current price is $278 million  You have watched hundreds of deals paid for by potential, of which you have not included.... |
|
|
|
Post by otherottawaguy on May 15, 2018 14:42:47 GMT -5
Lilly is not stupid. They have eyes, they can see. In my opinion Lilly would have nothing to lose and everything to gain. What would Lilly have to lose if Lilly partnered with MNKD/ Afrezza? Dr. Kendall. Insight. Connection. ... How much did Sanofi lose in its partnership with Mannkind? Digger since you like to flip the coin, let me do one for you. A much better question than yours is how much more has Sanofi made since effectively sidelining Afrezza? I would suffice to say that they have made more maintaining their market share than they ever intended to spend on Afrezza. OOG |
|
vin
Newbie
Posts: 19 
|
Post by vin on May 16, 2018 9:14:43 GMT -5
1.86 current PPS - enough said IMO And that is post reverse split! |
|
